← Back to Clinical Trials
Recruiting NCT02754544

NCT02754544 Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02754544
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Brain Neoplasm
Study Type INTERVENTIONAL
Enrollment 75 participants
Start Date 2016-07-22
Primary Completion 2027-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Direct Electrocortical StimulationElectrocorticography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 75 participants in total. It began in 2016-07-22 with a primary completion date of 2027-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This pilot clinical trial studies how well electrocorticography works in mapping functional brain areas during surgery in patients with brain tumors. Using a larger than the standard mapping grid currently used during brain tumor surgery or a high-definition grid for electrocorticogram brain mapping may help doctors to better identify which areas of the brain are active during specific limb movement and speech during surgery in patients with brain tumors.

Eligibility Criteria

Inclusion Criteria: * Patients undergoing a tumor resection at the University of Texas M. D. Anderson Cancer Center for a newly diagnosed as well as recurrent primary or metastatic brain tumor located in or adjacent to motor and/or speech brain areas * Patients \>= 18 years of age * Signed informed consent Exclusion Criteria: * Patients with significant neurological motor deficits of the upper extremities, and/or speech deficits, which would preclude them from performing the while awake intra-operative tasks at the discretion of the principal investigator (PI) * Patients who have impaired vision and/or hearing and whose performance could affect the study will be excluded at the discretion of the PI

Contact & Investigator

Central Contact

Sujit Prabhu, MD

✉ sprabhu@mdanderson.org

📞 713-792-2400

Principal Investigator

Sujit S Prabhu

PRINCIPAL INVESTIGATOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT02754544 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02754544 currently recruiting?

Yes, NCT02754544 is actively recruiting participants. Contact the research team at sprabhu@mdanderson.org for enrollment information.

Where is the NCT02754544 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT02754544 clinical trial?

NCT02754544 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Sujit S Prabhu at M.D. Anderson Cancer Center. The trial plans to enroll 75 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology